Keywords:stress, infertility, anxiety, Cyclodynon
In order to optimize the treatment of the primary stress-induced infertility the authors evaluated the effectiveness of complex therapy aimed at correcting the mental and emotional state, and the secondary hyperprolactinemia in 72 patients aged 24 to 40 years old with reproductive plans (38 women from the main group and 34 – the comparison group). The control group consisted of 30 healthy women.
Research of hormonal homeostasis of patients before treatment was showed a decrease in the average level of the pituitary hormones, low average concentrations of estradiol and progesterone, moderately elevated level of prolactin, and reduced indicators of endometrial thickness. The vast majority of women were in a heightened state of reactive and personal anxiety.
All of study participants received anti-stress therapy (phenibut + mebicar). In addition, the main group on the background of anti-stress treatment received the drug Cyclodynon, which has a mild dopaminergic action, contributing to inhibition of prolactin secretion and normalize the function of the hypothalamic-pituitary-ovarian system.
Within 3 months after the start of a complex anti-stress therapy in both groups the level of reactive anxiety was reduced, and the level of personal anxiety was reduced a lesser extent.
Dynamic control of hormones showed a significant decrease in the average concentrations of prolactin and increase of the synthesis of follicle-stimulating, luteinizing hormone, estradiol and progesterone in the blood serum of a group of women receiving Cyclodynon. In that group also was observed a significantly reduction the average concentration of prolactin and increased endometrial thickness. In the comparison group, which applied only anti-stress therapy, a similar trend was observed, but the full normalization not happened.
Within three years after treatment the pregnancy occurred in 32 (94.11%) women of the main group, and only 17 (50%) – of the comparison group.
The conclusion of research results: the combination of anti-stress and dopaminergic therapies is very effective. Consequently, it is possible to recommend assignment dopaminergic phytodrugs (in particular Cyclodynon) on background of anti-stress therapy for patients with stress-induced infertility with a view to correction of psychosomatic disorders and improvement of clinical pregnancy rates.
- Parashchuk, Y.S., Kalinovska, A.I., Gryshchenko, M.G., Parashchuk, V.Y. Infertility in marriage: tutorial. Kharkiv. KhNMU (2014): 124 p.
- Louis, G.M., Lum, K.J., Sundaram, R., et al. “Stress reduces conception probabilities across the fertile window: evidence in support of relaxation.” Fertil Steril 95 (2011): 2184–9.
- Piekarski, D.J., Zhao, S., Jennings, K.J., et al. “Gonadotropin-inhibitory hormone reduces sexual motivation but not lordosis behavior in female Syrian hamsters (Mesocricetus auratus).” Hormones and Behavior 64 (2013): 501–10.
- Sanders, R. «Blocking hormone could eliminate stress-induced infertility». Berkeley news online, Jan 12, 2015. Available from: [http:// news.berkeley.edu/2015/01/12/blocking-hormone-couldeliminate- stress-induced-infertility/], last accessed Nov 15, 2016.
- Sato, Y., Suzuki, N., Horita, H., et al. “Effects of long-term psychological stress on sexual behavior and brain catecholamine levels.” Journal of Andrology 17 (1996): 83–90.
- Son, Y.L., Ubuka, T., Millar, R.P., et al. «Gonadotropin-inhibitory hormone inhibits GnRH-induced gonadotropin subunit gene transcriptions by inhibiting AC/ cAMP/PKA-dependent ERK Pathway in L[beta]T2 cells.” Endocrinology 153 (2012): 2332–43.
- Anna C. Geraghty, Sandra E. Muroy, Sheng Zhao, et al. Knockdown of hypothalamic RFRP3 prevents chronic stress-induced infertility and embryo resorption. University of California. Berkeley, United States. Canadian Institute for Advanced Research, Canada.
- Batarshev, A.V. Basic psychological characteristics and self-identity: A Practical Guide for psychological diagnostics. St.-Petersburg. Publishing house “Rech” (2005): 44−49.
- The diagnostics of emotional and moral development. Ed. by I.B. Dermanova. St.-Petersburg. Publishing house “Rech” (2002): 124−6.
- Practical for Psychology states: Textbook. Ed. by prof. O.A. Prokhorov. St.-Petersburg. Publishing house “Rech” (2004): 121−2.
- Selye, H. Essays about adaptation syndrome. Moscow. Medgiz (1960).
- Morozov, V.N., Khadartsev, A.A. “To the modern interpretation of stress mechanisms.” VNMT 1 (2010).
- Paton, A., Harley, R., Harvey, T. “Editorial.” Vitex: A Newsletter for Lamiaceae & Verbenaceae Research 1 (2000), available from: [http://www.kew.org/data/ vitex/jan00.pdf], last accessed Nov 15, 2016.
- Merz, P.G., Gorkow, C., Schrödter, A., et al. “The effects of a special Agnus castus extract (BP1095E1) on prolactin secretion in healthy male subjects.” Exp Clin Endocrinol Diabetes 104.6 (1996): 447–53.
- Berger, D., Schaffner, W., Schrader, E., et al. “Efficacy of Vitex agnus castus L. extract Ze 440 in patients with pre-menstrual syndrome (PMS)”. Arch Gynecol Obstet 264.3 (2000): 150–3.
- Schellenberg, R. “Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study.” British Medical Journal 322.7279 (2001): 134–7.
- Milewicz, A., Gejdel, E., Sworen, H., et al. “Vitex agnus castus extract in the treatment of luteal phase defects due to latent hyperprolactinemia. Results of a randomized placebo-controlled double-blind study.” Arzneimittelforschung 43.7 (1993): 752–6.
- Dmitrieva, T.B., Drozdov, A.Z., Kogan, B.M. Main non-specific systems, which are adapting organism to acute and chronic stresses. Psychiatry of emergency situations. Guideline. Moscow (2004): 8–41.
- Balabolkin, M.I. Endocrinology. Moscow. Medicine (1989): 416 p.
- Vaks, V.V. “Hyperprolactinemia: causes, clinical features, diagnosis and treatment.” Consilium medicum 3.11 (2001): 516–25.
- Dzeranova, L.K., Tabeeva, K.I., Goncharov, N.P., et al. “Macroprolactinemia.” Problems of reproduction 11.2 (2005): 60–5.
- Colao, A., di Sarno, A., Pivonello, R., et al. “Dopamine receptor agonists for treating prolactinomas.” Expert Opin Investig Drugs 11.6 (2002): 787–800.
- Delitala, G. Hyperprolactinaemia: causes, biochemical diagnosis and tests of prolactin secretion. Clinical Endocrinology ed. by A. Grossman. Oxford (1992): 123–47.
- Molitch, M.E. “Disorders of prolactin secretion.” Endocrinol Metab Clin North Am 30.3 (2001): 585–610.
- Olukoga, A.O. “Macroprolactinaemia is clinically important.” J Clin Endocrinol Metab 87.10 (2002): 4833–4.
- Schlechte, J.A. “Editoral: the macroprolactin problem.” J Clin Endocrinol Metab 87.12 (2002): 5408–9.
- Toldy, E., Zoltan, L., Szabolcs, I. “Hyperprolactinemia.” Endocrine 22.3 (2003): 267–73.
- Akmaev, I.G. “Neuroimmunoendocrinology: origins and prospects of development.” Advances of Physiological Sciences 34.4 (2003): 4–15.
- Shaliapina, V.G., Rakitskaya, V.V. “The reactivity of the pituitary-adrenocortical system to stress in rats with active and passive strategies of behavior.” I.M. Sechenov Russ. Physiol. Journ. 89.5 (2003): 585–90.
- Aguilera, G., Kiss, A., Liu, Y., Kamitakahara, A. Stress 10.2 (2007): P. 153–61.
- Ben-Jonathan, N., Liby, K., McFarland, M., Zinger, M. “Prolactin as an autocrine/paracrine growth factor in human cancer.” Trends Endocrinol Metab 13.6 (2002): 245–50.
- Hinuma, S., Shintani, Y., Fukusumi, S., et al. “New neuropeptides containing carboxy-terminal RFamide and their receptor in mammals.” Nat Cell Biol 2.10 (2000): 703–8.
- Tsutsui, K., Saigoh, E., Ukena, K., et al. “A novel avian hypothalamic peptide inhibiting gonadotropin release.” Biochem Biophys Res Commun 275.2 (2000): 661–7.
- Yin, H., Ukena, K., Ubuka, T., Tsutsui, K. “A novel G protein-coupled receptor for gonadotropininhibitory hormone in the Japanese quail (Coturnix japonica): identification, expression and binding activity.” J Endocrinol 184.1 (2005): 257–66.
- Serov, V.N., Zvenigorodskiy, I.N. Diagnosis of gynecological diseases with a course of pathological anatomy. Moscow. BINOM. Knowledge Laboratory (2003): 139 p.
How to Cite
Copyright (c) 2016 Н. В. Косей, С. И. Регеда, Н. В. Яроцкая, А. А. Горохова
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.